Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07232732 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
A Phase 1 study of Healthy and Obesity, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 3
- Study locations
NCT07232732: Recruiting Phase 1 study of Healthy and Obesity, sponsored by Eli Lilly and Company.
NCT07232732 is a Phase 1 study of Healthy and Obesity that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 120 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07232732, a Phase 1 study of Healthy and Obesity, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.
Primary Outcome
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
Conditions Studied
Interventions
- DRUG LY3549492
Study Locations (3)
Florida
- Fortrea Clinical Research Unit - Daytona Beach
Texas
- Fortrea Clinical Research Unit - Dallas
Wisconsin
- Fortrea Clinical Research Unit - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What NCT07232732 shows while recruiting
NCT07232732 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which LY3549492 is the first listed.
NCT07232732 reports a single indexed study location in Florida, Texas, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07232732 about?
NCT07232732 is a clinical study titled "A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity". The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.
What is the current status of trial NCT07232732?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-10-27. Estimated completion is 2026-07.
What conditions does trial NCT07232732 study?
This clinical trial studies the following conditions: Healthy, Obesity, Overweight.
What interventions are being tested in trial NCT07232732?
The interventions under investigation include: LY3549492 (DRUG).
Who is sponsoring clinical trial NCT07232732?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07232732 being conducted?
This trial has 3 study locations across Florida, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07232732's enrollment target sits among peer trials
120 182nd of 1090 higher than 896 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI